ComputeD tomogrAphy angiographY for Left atrIal appendaGe tHrombus Detection in Acute Ischemic sTroke (DAYLIGHT) Trial (DAYLIGHT)
Primary Purpose
Acute Ischemic Stroke, Transient Ischemic Attack, Left Atrial Appendage Thrombosis
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
extended CTA
Sponsored by
About this trial
This is an interventional prevention trial for Acute Ischemic Stroke
Eligibility Criteria
Inclusion Criteria:
- All adult patients with a suspected cerebrovascular event who are evaluated in the Emergency Department or the Urgent Stroke Prevention Clinic at University Hospital, London Health Sciences Centre, London, Ontario, Canada.
- A confirmed diagnosis of stroke or TIA is not mandatory.
Exclusion Criteria:
- Allergy to iodinated contrast agents
- Pregnancy
- Lack of a peripheral vein access for intravenous contrast administration
- Any contraindication for the clinical use of a CTA for hyperacute stroke care (e.g., end-stage renal disease that contraindicates a CTA), and active or past cancer of the head, neck, or chest)
Sites / Locations
- London Health Sciences CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
standard CTA
extended CTA
Arm Description
Standard CTA performed as standard of care for Stroke Workup
The standard CTA will be extended 3 cm below the carina with the aim of increase the LAA thrombus detection
Outcomes
Primary Outcome Measures
Primary Efficacy Outcome: newly diagnosed LAA thrombus
The proportion of participants with newly diagnosed LAA thrombus at 120 post-stroke and no history of atrial fibrillation. The reason for choosing 120 days of follow-up is that most follow-up visits after the stroke workup is completed are done at 90 days but there may be some delays in some cases. We aim to ensure the largest proportion possible of patients with a complete workup at the time of the study follow-up visit.
Secondary Outcome Measures
Secondary Efficacy Outcome: patients anticoagulated after the CVA event
The proportion of patients receiving oral anticoagulation at 120 days after the qualifying stroke or TIA.
Full Information
NCT ID
NCT05522244
First Posted
August 17, 2022
Last Updated
October 4, 2023
Sponsor
Lawson Health Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT05522244
Brief Title
ComputeD tomogrAphy angiographY for Left atrIal appendaGe tHrombus Detection in Acute Ischemic sTroke (DAYLIGHT) Trial
Acronym
DAYLIGHT
Official Title
ComputeD tomogrAphy angiographY for Left atrIal appendaGe tHrombus Detection in Acute Ischemic sTroke (DAYLIGHT) Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 17, 2023 (Actual)
Primary Completion Date
March 2024 (Anticipated)
Study Completion Date
March 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lawson Health Research Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Embolic strokes of undetermined source (ESUS) represent a subset of cryptogenic strokes that are suspected to have an occult embolic source. The risk of stroke recurrence in patients with ESUS varies between 1.9%/year and 19.0%/year depending on the prevalence of vascular risk factors. Part of the elevated recurrence rate is due to the inability to identify high-risk treatable causes such as cardiac thrombi as those found in the LAA.The most frequently used diagnostic method in clinical practice to detect an LAA thrombus is transesophageal echocardiography (TEE). However, the relatively low availability, higher cost, and invasive nature of TEE limit its large-scale usability. In most stroke centers, patients presenting with an acute ischemic stroke or TIA undergo a tomography (CT) angiography (CTA) of the neck and intracranial vessels. This standard of care CTA (sCTA) classically includes the aortic arch, the higher portion of the ascending/descending aorta, and the rostral portion of the cardiac chambers, but does not involve the LAA. A recent study performed among 300 patients with an acute ischemic stroke showed an overall LAA thrombus detection of 6.6% and 15% in patients with AF by extending the CTA 3 cm below the carina.This is an extraordinarily high prevalence of LAA compared to 0.5% to 4.8% of intracardiac thrombi identified on TEE in most previous studies. The major limitation of previous CTA and TEE studies is their observational design, so the differing prevalence of LAA thrombi could be explained by dissimilar population characteristics. Based on the methodological limitation of prior studies and the promising role of extended CTAs (eCTA), a randomized controlled trial comparing eCTA + standard of care stroke workup vs. sCTA + standard of care stroke workup is needed.
Detailed Description
Between 16% and 25% of patients with ischemic strokes do not have an identifiable cause after a full stroke workup, and their strokes are classified as cryptogenic. Embolic strokes of undetermined source (ESUS) represent a subset of cryptogenic strokes that are suspected to have an occult embolic source. The risk of stroke recurrence in patients with ESUS varies between 1.9%/year and 19.0%/year depending on the prevalence of vascular risk factors. Part of the elevated recurrence rate is due to the inability to identify high-risk treatable causes such as cardiac thrombi as those found in the LAA.The most frequently used diagnostic method in clinical practice to detect an LAA thrombus is transesophageal echocardiography (TEE). However, the relatively low availability, higher cost, and invasive nature of TEE limit its large-scale usability. In most stroke centers, patients presenting with an acute ischemic stroke or TIA undergo a tomography (CT) angiography (CTA) of the neck and intracranial vessels. This standard of care CTA (sCTA) classically includes the aortic arch, the higher portion of the ascending/descending aorta, and the rostral portion of the cardiac chambers, but does not involve the LAA. A recent study performed among 300 patients with an acute ischemic stroke showed an overall LAA thrombus detection of 6.6% and 15% in patients with AF by extending the CTA 3 cm below the carina.This is an extraordinarily high prevalence of LAA compared to 0.5% to 4.8% of intracardiac thrombi identified on TEE in most previous studies. The major limitation of previous CTA and TEE studies is their observational design, so the differing prevalence of LAA thrombi could be explained by dissimilar population characteristics. Based on the methodological limitation of prior studies and the promising role of extended CTAs (eCTA), a randomized controlled trial comparing eCTA + standard of care stroke workup vs. sCTA + standard of care stroke workup is needed.
Demonstrating that performing an eCTA can significantly increase the detection of LAA thrombi compared to sCTA has three important implications with the potential to improve clinical practice, patients' outcomes, and clinical guidelines. First, proving that eCTA increases de detection of LAA thrombi in stroke patients in a randomized controlled trial (highest level of evidence) may result in guidelines recommending this novel approach and stroke sites adopting this technique globally. Second, the higher detection of LAA thrombi may increase the use of oral anticoagulants, which have proven efficacy for the prevention of recurrent strokes in patients with cardiac thrombi, ultimately resulting in fewer stroke recurrences. However, proving the latter concept would require a larger randomized clinical trial with stroke recurrence as the primary efficacy endpoint. Third, the LAA is the most frequent source of thromboembolism in patients with AF and LAA thrombi are associated with increased detection of AF on cardiac rhythm monitoring, implying that finding an LAA thrombus may help improve the selection of patients who could benefit from prolonged cardiac monitoring after stroke.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Ischemic Stroke, Transient Ischemic Attack, Left Atrial Appendage Thrombosis
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
583 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
standard CTA
Arm Type
No Intervention
Arm Description
Standard CTA performed as standard of care for Stroke Workup
Arm Title
extended CTA
Arm Type
Experimental
Arm Description
The standard CTA will be extended 3 cm below the carina with the aim of increase the LAA thrombus detection
Intervention Type
Diagnostic Test
Intervention Name(s)
extended CTA
Intervention Description
Extending the standard CTA 3 cm below the carina.
Primary Outcome Measure Information:
Title
Primary Efficacy Outcome: newly diagnosed LAA thrombus
Description
The proportion of participants with newly diagnosed LAA thrombus at 120 post-stroke and no history of atrial fibrillation. The reason for choosing 120 days of follow-up is that most follow-up visits after the stroke workup is completed are done at 90 days but there may be some delays in some cases. We aim to ensure the largest proportion possible of patients with a complete workup at the time of the study follow-up visit.
Time Frame
120 days after the qualifying stroke or TIA.
Secondary Outcome Measure Information:
Title
Secondary Efficacy Outcome: patients anticoagulated after the CVA event
Description
The proportion of patients receiving oral anticoagulation at 120 days after the qualifying stroke or TIA.
Time Frame
120 days after the qualifying stroke or TIA.
Other Pre-specified Outcome Measures:
Title
Primary Safety Outcome: door to sCTA time vs door to eCTA
Description
Door to CTA completion will be measured to ensure that the eCTA will not result in substantial delays in patient care. Although we anticipate that the eCTA will only be 3 seconds longer than the sCTA, we will aim to document any possible differences
Time Frame
Through study completion, an average of 1 year
Title
Secondary Safety Outcome: door to tPA vs door to EVT
Description
Door to needle time in patients receiving intravenous thrombolysis and Door to groin puncture in patients receiving a mechanical thrombectomy.
Time Frame
Through study completion, an average of 1 yea
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All adult patients with a suspected cerebrovascular event who are evaluated in the Emergency Department or the Urgent Stroke Prevention Clinic at University Hospital, London Health Sciences Centre, London, Ontario, Canada.
A confirmed diagnosis of stroke or TIA is not mandatory.
Exclusion Criteria:
Allergy to iodinated contrast agents
Pregnancy
Lack of a peripheral vein access for intravenous contrast administration
Any contraindication for the clinical use of a CTA for hyperacute stroke care (e.g., end-stage renal disease that contraindicates a CTA), and active or past cancer of the head, neck, or chest)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Diana Ayan, MSc
Phone
519-685-8500
Ext
35826
Email
diana.ayan@lhsc.on.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Moussa
Phone
519-685-8500
Email
jennifer.moussa@lhsc.on.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luciano Sposato, MD
Organizational Affiliation
London Health Sciences Center, Western University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rodrigo Bagur, MD
Organizational Affiliation
London Health Sciences Center, Western University
Official's Role
Principal Investigator
Facility Information:
Facility Name
London Health Sciences Centre
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Ayan, MSc
Phone
+1(519) 685-8500
Ext
35286
Email
diana.ayan@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Jennifer Moussa
Phone
+1(519) 685-8500
Ext
33110
Email
jennifer.moussa@lhsc.on.ca
First Name & Middle Initial & Last Name & Degree
Luciano Sposato, MD
12. IPD Sharing Statement
Learn more about this trial
ComputeD tomogrAphy angiographY for Left atrIal appendaGe tHrombus Detection in Acute Ischemic sTroke (DAYLIGHT) Trial
We'll reach out to this number within 24 hrs